Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

Journal:
The Lancet
Published:
Affiliations:
30
Authors:
30
Institutions Authors Share
Jazz Pharmaceuticals PLC, United States of America (USA)
4.033333
0.13
Genentech, Inc., United States of America (USA)
3.033333
0.10
Airway Research Center North (ARCN), Germany
1.033333
0.03
Chungbuk National University Hospital, South Korea
1.033333
0.03
Hospital de la Santa Creu i Sant Pau, Spain
1.033333
0.03
Evangelische Lungenklinik Berlin, Germany
1.033333
0.03
Taichung Veterans General Hospital, Taiwan
1.033333
0.03
Gülhane Training and Research Hospital, Turkey
1.033333
0.03
Yale University, United States of America (USA)
1.033333
0.03
Greater Poland Centre for Pulmonology and Thoracic Surgery named after Eugenia and Janusz Zeyland (), Poland
1.033333
0.03
Georgetown Lombardi Comprehensive Cancer Center, United States of America (USA)
1.033333
0.03
Virgen del Rocío University Hospital, Spain
1.033333
0.03
Hetényi Géza Kórház, Hungary
1.033333
0.03
Samsung Medical Center (SMC), South Korea
1.033333
0.03
European Interbalkan Medical Center (EIMC), Greece
1.033333
0.03
University Hospital of Lausanne (CHUV), UNIL, Switzerland
1.033333
0.03
F. Hoffmann-La Roche Ltd., Switzerland
1.033333
0.03
John Paul II Hospital, Poland
1.033333
0.03
Fox Chase Cancer Center (FCCC), United States of America (USA)
1.033333
0.03
Altinbas University, Turkey
1.033333
0.03
Sarah Cannon Research Institute (SCRI), United States of America (USA)
0.533333
0.02
Tennessee Oncology, United States of America (USA)
0.533333
0.02
Yıldırım Beyazıt University (YBU), Turkey
0.533333
0.02
Ankara Bilkent City Hospital, Turkey
0.533333
0.02
The Christie NHS Foundation Trust, United Kingdom (UK)
0.533333
0.02
The University of Manchester (UoM), United Kingdom (UK)
0.533333
0.02
Hospital Universitario 12 de Octubre, Spain
0.283333
0.01
Spanish National Cancer Research Centre (CNIO), Spain
0.283333
0.01
Complutense University of Madrid (UCM), Spain
0.283333
0.01
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
0.283333
0.01